drugset / Trial / NCT06643637
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy, adult participants.
Timeline
- Start
- 2024-11-08
- Primary completion
- 2025-03-12
- Completion
- 2025-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Psilocybin | Other / unclassified | — | Oral |
Indications
No indication recorded.